SUBSCRIBE TO OUR RSS

Business Finance Health Law/Policy Tech/Innovation

font size

print

INTERVIEW

Adapting for Success

Watch Biobusiness.tv interview with G. Steven Burrill about the publication of Biotech 2010-Life Sciences: Adapting for Success, his 24th annual report on the biotechnology industry.


Adapting to Change, an Interview with G. Steve Burrill (1/6)	No Real Healthcare Reform, Only Insurance Reform (2/6)	Financing Biotech in 2010 (3/6)

From Personalized Medicine to Preemptive Medicine (4/6)	Stem Cells and Other Promising New Technologies (5/6)	FAST Word Association Game, with Steve Burrill (6/6)

For more information about Biotech 2010 - Life Sciences: Adapting for Success, Burrill & Company's 24th annual report on the life sciences industry, click here. You can download the table of content by clicking here.

Become a fan on Facebook of Biotech 2010-Life Sciences: Adapting for Succes, Burrill & Company's 24th annual report on the biotech industry

Home |
Email |
Print |

[Please login to post comments]

Other recent stories

An Exit Strategy
Capstone gives investors puts in case they want out after mid-stage trial results. Read More
Healthcare Reform Opens the Door to Copycat Biologics
Podcast: March 29, 2010 Read More
Yes We Can
Healthcare reform will carry a staggering tab, but the good news is we can fix that with innovation. Read More
A Blow to Cell Therapeutics
FDA advisory panel unanimously finds clinical trial data inadequate to approve Seattle company's cancer drug. Read More
Getting Personal
Pfizer leads $15.5 million round for diagnostics maker Nodality. Read More
Positive Results, Negative Consequences
Stopping clinical trials early often exaggerates treatment effects. Read More
Avoiding Death
Four preventable risk factors reduce U.S. life expectancy and lead to health disparities. Read More
Another biotech IPO in the offing
CorMedix prices its initial public offering. Read More
Jury Hits Pfizer with a $142.1 Million Verdict in Neurontin Racketeering Case
The weekly round-up of failed trials, missed targets and other business mishaps. Read More
Practice, Not Theory
Federal appeals court ruling could be blow to universities' ability to win patents for ideas. Read More

Congress’s Final Votes on Health Care Set Stage for Sales Job
Bloomberg
Pfizer Told to Pay $142.1 Million for Neurontin Marketing Fraud
Bloomberg
More Doctors Giving Up Private Practices
The New York Times
Final Votes in Congress Cap Battle on Health Bill
The New York Times
Doctors’ Thoughts on Cutting Health Care Costs
The New York Times
Sex virus blamed for rise in head and neck cancers
Reuters
Healthcare costs burden more Americans: study
Reuters
U.S. Stocks Rise as Drug Shares Rally After House OKs Overhaul
Bloomberg
U.S. employer healthcare costs up 7.3 percent in 2009
Reuters
In Health Care Reform, Boons for Hospitals and Drug Makers
The New York Times

» See more